Share price movers - October 2019

Edwin Elmirst
**Top Gains**

- **Reata Pharmaceuticals**
  - +157%
  - Phase II Mosle trial of omaveloxolone in Friedreich’s ataxia meets primary endpoint.

- **Constellation Pharmaceuticals**
  - +114%
  - Data from the Manifest trial of CPI-0610 in myelofibrosis will be presented at ASH 2019.

- **ReNeuron Group**
  - +99%
  - UCB agrees to buy company for $2.1bn.

- **Kiadis Pharma**
  - +78%
  - Alexion agrees to buy company for $930m upfront.

- **Assembly Biosciences**
  - +68%
  - Data on ABI-H0731 and ABI-H2158 in chronic hepatitis B to be in a late-breaking poster at AASLD.

**Top Losses**

- **ReNeuron Group**
  - -51%
  - Further data from phase II trial of company’s human retinal progenitor cells in retinitis pigmentosa disappoint.

- **Botanix Pharmaceuticals**
  - -56%
  - Phase II trial of BTX-1503 in acne fails to meet primary endpoint.

- **Severe Pharmaceuticals**
  - -58%
  - Company no longer expects EU approval of ATIR101 in late-stage blood cancer.

- **Cyclerion Therapeutics**
  - -67%
  - FDA recommends against company filing Molgradex for autoimmune pulmonary alveolar proteinosis following failure of Impala study.

- **Assembly Biosciences**
  - -80%
  - Phase II trials of praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction fail to meet primary endpoints.